Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis

Modern Pathology

Volumn 24, Issue 11, 2011, Pages 1470-1479

  Monzon, Federico A ^a,b   Alvarez, Karla ^a   Peterson, Lief ^a   Truong, Luan ^a   Amato, Robert J ^c   Hernandez Mcclain, Joan ^c   Tannir, Nizar ^d   Parwani, Anil V ^e   Jonasch, Eric ^d  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

angiogenesis; chromosomal imbalances; EPAS1; HIF1A; hypoxia inducible factor; prognosis; renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MESSENGER RNA; SORAFENIB;

ARTICLE; CANCER SURVIVAL; CHROMOSOME 14Q; CHROMOSOME 8Q; CHROMOSOME 9P; CHROMOSOME LOSS; CLEAR CELL CARCINOMA; CLEAR CELL KIDNEY CARCINOMA; CLINICAL ARTICLE; GENETIC ASSOCIATION; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 14; GENE EXPRESSION PROFILING; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 80455174760     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.107     Document Type: Article

References (38)

1. American Cancer Society. Cancer Facts & Figures 2008 American Cancer Society: Atlanta 2008.
2. DeVita VT, Hellman S, Rosenberg SA. Cancer, Principles and Practice of Oncology, 6th edn. Lippincott, Williams & Wilkins: Philadelphia, 2001.
3. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353:2477-2490. (Pubitemid 41770167)
4. Lam JS, Shvarts O, Leppert JT, et al. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 2005;173:1853-1862. (Pubitemid 40675199)
5. Amin MB, Amin MB, Tamboli P, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Path 2002;26:281-291. (Pubitemid 34184451)
6. Delahunt B, Bethwaite PB, Nacey JN. Outcome prediction for renal cell carcinoma: evaluation of prognostic factors for tumours divided according to histological subtype. Pathology 2007;39:459-465. (Pubitemid 47450591)
7. Motzer RJ, Bacik J, Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experience. Clin Cancer Res 2004;10(Pt 2):6302S-6303S. (Pubitemid 39287482)
8. Amin MB, Tamboli P. Impact of histologic subtyping of renal epithelial neoplasms: authors' reply. Am J Surg Path 2003;27:1022-1024.
9. Monzon FA, Hagenkord J, Lyons-Weiler M, et al. Whole genome SNP arrays as a potential diagnostic tool for the detection of characteristic chromosomal aberrations in renal epithelial tumors. Mod Pathol 2008;21:1-10.
10. Yoshimoto T, Matsuura K, Karnan S, et al. High-resolution analysis of DNA copy number alterations and gene expression in renal clear cell carcinoma. J Pathol 2007;213:392-401. (Pubitemid 350206511)
11. Kardas I, Mrozek K, Babinska M, et al. Cytogenetic and molecular findings in 75 clear cell renal cell carcinomas. Oncol Rep 2005;13:949-956.
12. Gunawan B, Huber W, Holtrup M, et al. Prognostic impacts of cytogenetic findings in clear cell renal cell carcinoma: gain of 5q31-qter predicts a distinct clinical phenotype with favorable prognosis. Cancer Res 2001;61:7731-7738. (Pubitemid 33049357)
13. Brunelli M, Eccher A, Gobbo S, et al. Loss of chromosome 9p is an independent prognostic factor in patients with clear cell renal cell carcinoma. Mod Pathol 2008;21:1-6.
14. Moch H, Presti Jr JC, Sauter G, et al. Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma. Cancer Res 1996;56:27-30. (Pubitemid 26010380)
15. Klatte T, Rao PN, de Martino M, et al. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol 2009;27: 746-753.
16. La Rochelle J, Klatte T, Dastane A, et al. Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma. Cancer 2010;116: 4696-4702.
17. Gordan JD, Lal P, Dondeti VR, et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008;14:435-446.
18. Kim HJ, Shen SS, Ayala AG, et al. Virtual-karyotyping with SNP microarrays in morphologically challenging renal cell neoplasms: a practical and useful diagnostic modality. Am J Surg Pathol 2009;33:1276-1286.
19. Arai E, Ushijima S, Tsuda H, et al. Genetic clustering of clear cell renal cell carcinoma based on array-comparative genomic hybridization: its association with DNA methylation alteration and patient outcome. Clin Cancer Res 2008;14:5531-5539.
20. Jonasch E, Wood CG, Matin SF, et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:4076-4081.
21. Jonasch E, Corn P, Pagliaro LC, et al. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 2010;116:4-7.
22. Lyons-Weiler M, Hagenkord J, Sciulli CM, et al. Optimization of the Affymetrix GeneChip mapping 10K 2.0 assay for routine clinical use on formalin fixed paraffin embedded tissues. Diagn Mol Pathol 2008; 17:3-13.
23. Yamamoto G, Nannya Y, Kato M, et al. Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet 2007;81: 114-126. (Pubitemid 47001161)
24. Lefever S, Vandesompele J, Speleman F, et al. RTPrimerDB: the portal for real-time PCR primers and probes. Nucleic Acids Res 2009;37, Database issue D942-D945.
25. Zhao S, Fernald RD. Comprehensive algorithm for quantitative real-time polymerase chain reaction. J Comput Biol 2005;12:1047-1064. (Pubitemid 41580022)
26. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335:865-875.
27. Liao D, Johnson R. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Met Reviews 2007; 26:281-290. (Pubitemid 47101669)
28. Young AN, Master VA, Paner GP, et al. Renal epithelial neoplasms: diagnostic applications of gene expression profiling. Adv Anat Pathol 2008;15:28-38. (Pubitemid 351627651)
29. Lidgren A, Hedberg Y, Grankvist K, et al. Hypoxia-inducible factor 1[alpha] expression in renal cell carcinoma analyzed by tissue microarray. Eur Urol 2006;50:1272-1277. (Pubitemid 44692925)
30. Gordan JD, Bertout JA, Hu C-J, et al. HIF-2a promotes hypoxic cell proliferation by enhancing c-Myc transcriptional activity. Cancer Cell 2007;11: 335-347. (Pubitemid 46518312)
31. Toschi A, Lee E, Gadir N, et al. Differential dependence of hypoxia-inducible factors1a and 2a on mTORC1 and mTORC2. J Biol Chem 2008;283: 34495-34499.
32. Moinzadeh P, Breuhahn K, Stutzer H, et al. Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade-results of an explorative CGH meta-analysis. Br J Cancer 2005;92:935-941. (Pubitemid 40462642)
33. Patil MA, Gutgemann I, Zhang J, et al. Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma. Carcinogenesis 2005;26:2050-2057. (Pubitemid 41672192)
34. Bae MK, Ahn MY, Jeong JW, et al. Jab1 interacts directly with HIF-1alpha and regulates its stability. J Biol Chem 2002;277:9-12.
35. Alimov A, Sundelin B, Wang N, et al. Loss of 14q31-q32. 2 in renal cell carcinoma is associated with high malignancy grade and poor survival. Int J Oncol 2004;25:179-185.
36. Mitsumori K, Kittleson JM, Itoh N, et al. Chromosome 14q LOH in localized clear cell renal cell carcinoma. J Pathol 2002;198:110-114. (Pubitemid 34966214)
37. Louis DN. Molecular pathology of malignant gliomas. Ann Rev Pathol: Mech Dis 2006;1:97-117.
38. Jaffe ES. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press; Oxford University Press (distributor): Lyon, Oxford, 2001.